Alert: Because flu cases are on the rise, children 12 and younger will be restricted from visiting hospitals and certain inpatient facilities. Learn more.

Research and Clinical Trials

Valgan Toddler
Brief Description  
Gancliclovir is an IV drug that has been shown to decrease the chances of hearing loss in infants with congenitgal cytomegalovirus (CMV). Since CMV-assocaitged hearing loss often emerges after infancy, there is an unmet need for a treatment option for the toddler population. Valganciclovir is the oral form of ganciclovir and we would like to see if giving toddlers with hearing loss and congenital CMV valganciclovir for 6 weeks will stabilize hearing loss.
Who may be Eligible  
Ages 1 month through 3 years old; diagnosed with sensorineural hearing loss (SNHL); diagnosed with CMV
Cytomegalovirus (CMV)
Start Date  
IRB Number  
Principal Investigator  
Ahmed, Amina
Contact Name  

For More Information, Contact  Wendy  S, Upton
Phone:  (704) 333-4208  Fax:  (704) 333-7924  
Email:  Wendy.upton@carolinas.org
Address:1628 E. Morehead Street Charlotte ,NC 28207